NEFL antibody
- Known as:
- NEFL (anti-)
- Catalog number:
- orb66923
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- NEFL antibody
Related genes to: NEFL antibody
- Gene:
- NEFL NIH gene
- Name:
- neurofilament light
- Previous symbol:
- -
- Synonyms:
- NFL, CMT1F, CMT2E, NF68, PPP1R110
- Chromosome:
- 8p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: NEFL antibody
Related articles to: NEFL antibody
- Interleukin-6 (IL-6) plays a pivotal role in autoimmune inflammation through its effects on B-cell differentiation, Th17 expansion, and regulatory T-cell suppression. Given ocrelizumab's (OCR) mechanism of selective CD20 B-cell depletion, baseline IL-6 levels have been hypothesized to predict disease activity and long-term outcomes in multiple sclerosis (MS). However, the prognostic value of serum IL-6 in OCR-treated patients remains unclear. Therefore, the objective of this study was to evaluate whether baseline and longitudinal serum IL-6 levels can predict clinical and radiological outcomes in OCR-treated MS patients. - Source: PubMed
Publication date: 2026/08/21
Kölsche TristanHagler RamonaHuntemann NiklasMasanneck LarsMüller MarcKutsojannis Bela JesajaBoeckers Joshua MKirschner PatriciaSchulze-Bosse KarinAktas OrhanMeuth Sven GRuck TobiasPawlitzki Marc - Older adults living with frailty are prone to adverse events upon acute hospitalization. Frailty biomarkers aiding early identification are lacking. This study explores frailty and Alzheimer's disease (AD)-related biomarkers. - Source: PubMed
Goll JonasMartinaityte IevaKirsebom Bjørn-EivindHalvorsen Dag SeegerGonzalez-Ortiz FernandoZetterberg HenrikFladby TormodGundersen Mona Dixon - Serum neurofilament light chain (sNfL) reflects inflammatory axonal damage in relapsing multiple sclerosis (RMS). Longitudinal sNfL dynamics may aid treatment response assessment, although data on expected changes under disease-modifying treatments remain limited, particularly in real-world practice. This study evaluated whether on-treatment changes in sNfL were associated with subsequent evidence of disease activity (EDA) and whether they provided complementary information to established treatment response scoring systems (TRSS). - Source: PubMed
Publication date: 2026/08/20
Fernández VictoriaPappolla AgustinCarbonell-Mirabent PereCastillo MireiaGutierrez LuciaFissolo NicolasLeón Plaza OlmoBraga NathaneAriño HelenaAuger CristinaBollo LucaCastilló JoaquínCarvajal ReneCobo-Calvo AlvaroEspejo CarmenGalan IngridGuio-Sánchez ClaudiaLa Puma DelonMidaglia Luciana SoledadMongay-Ochoa NeusNos CarlosOtero-Romero SusanaAcevedo Breogan RodriguezSastre-Garriga JaumeTagliani PaulaTur CarmenVidal-Jordana AngelaVilaseca AndreuVillacieros-Álvarez JavierZabalza AnaRovira ÀlexTintore MarComabella ManuelRio JordiMontalban XavierArrambide Georgina - The plasma proteomic signatures underlying cerebrovascular disease (CeVD) remains poorly understood. - Source: PubMed
Sim Ming AnnHilal SaimaTromp JasperTan Eugene S JDoecke JamesLiew Oi WahCai Vera YuanChan Siew PangChong Eddie Jun YiToh AnqiYeow Tan BoonVenketasubramanian NarayanaswamyBarascuk-Michaelsen NatashaSim DavidLeong Gerard Kui TohYeo Daniel Poh ShuanOng Hean YeeLing Lieng HsiLam CarolynLai Mitchell K PChoi HyungwonRichards Arthur MarkChen Christopher L H - Evidence regarding the association between physical activity (PA) and Alzheimer's disease (AD)-related biomarkers is scarce and inconsistent. - Source: PubMed
Iso-Markku PaulaTu Xin MRissman Robert AGillespie Nathan AElman Jeremy AFennema-Notestine ChristinePanizzon Matthew SReynolds Chandra ALyons Michael JKremen William SFranz Carol E